Another $1.5 million will support early work on an implant designed to release birth control over time.

Daré Bioscience (NASDAQ: DARE) received $1.5 million in additional funding for its DARE-LARC1 contraceptive implant. The company believes its DARE-IDDS platform could extend to other chronic diseases, like obesity and diabetes. Daré is exploring strategic collaborations and expects to advance DARE-LARC1 toward an IND submission.

Original reporting
Published Oct 30, 2026, 12:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$DARE
Neutral
high confidence
Mentioned
$DARE
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$DARENeutralLow
01

Why it matters

The grant confirms progress toward IND filing but does not yet indicate commercial viability.

02

Market read

Funding news is a modest, non‑dilutive capital event with limited immediate price impact.

03

What to watch

Potential future collaborations in obesity/diabetes could unlock larger markets beyond contraception.

Relevance 5/10Novelty 5/10Timing: today

Background

Daré Bioscience focuses on women's health devices; the DARE‑IDDS platform aims to deliver programmable drug release.

Company-level read

Ticker impact

$DARENeutralHigh confidence
Context

Daré Bioscience announced receipt of an additional $1.5 million grant installment, bringing total funding to about $X million for its DARE‑IDDS platform.

Expected impact

likely slight upside as the market prices in non‑dilutive funding for the contraceptive platform

Evidence & confidence

Funding is small but confirms progress and validates the platform, reducing near‑term financing risk.

Market effects

Shows continued investor interest in long‑acting drug‑delivery biotech, may encourage similar grant pursuits.

Limited to U.S. biotech funding environment.

Minimal; primarily affects Daré Bioscience and niche contraceptive device space.

Counterpoint

The modest grant size may signal limited commercial upside, suggesting caution.

Key entities

  • Daré Bioscience, Inc.

    NASDAQ‑listed biotech developing programmable implantable contraceptive devices.

Related articles

$DAREMed

Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement

Dare Bioscience, Inc. (DARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington

$DAREMedAI 8/10

Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting

Daré Bioscience (NASDAQ: DARE) will present Phase 1 data on its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study showed lower systemic exposure compared to oral sildenafil, with no serious adverse events. The company is developing the cream as a potential treatment for female sexual arousal disorder (FSAD), for which there are currently no FDA-approved treatments.

$DAREMedAI 8/10

Daré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure

Daré Bioscience (DARE) reported Phase 1 data for its Sildenafil Cream, showing lower systemic exposure than oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and found significantly lower plasma concentrations for topical administration. The cream is being developed for women's sexual health. DARE stock is currently trading at $0.71, up 0.69%.